ArticleFrontiers in cardiovascular medicine2026
Serum endocan levels in non-ST segment elevation myocardial infarction patients.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endothelial dysfunction and inflammation play a key role in the pathophysiology of acute coronary syndrome (ACS). Endocan has emerged as a novel biomarker reflecting endothelial activation. Objective: To investigate serum endocan levels in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and their association with coronary stenosis severity. Methods: This prospective observational study included 81 NSTEMI patients undergoing coronary angiography. Patients were classified into clinically significant coronary stenosis and non-significant coronary stenosis groups. Serum endocan levels were measured at admission. Results: Patients who underwent coronary angiography ( Conclusion: Endocan levels are elevated in NSTEMI patients with clinically significant coronary stenosis and may reflect endothelial dysfunction and atherosclerotic burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.